首页 工具
登录
全部产品 抑制剂&激动剂 化合物库 天然产物 技术服务 重组蛋白 会员中心 联系我们
购物车
抑制剂&激动剂 血管生成 凋亡 自噬 细胞周期 表观遗传 细胞骨架 DNA损伤和修复 内分泌与激素 G蛋白偶联受体 免疫与炎症 JAK/STAT信号通路 MAPK信号通路 离子通道 代谢 微生物学 神经科学
化合物库 活性化合物库 •   通用已知活性库 •   上市状态分类 •   疾病类型分类 •   通路靶点分类 天然产物库 •   高通量筛选天然产物库 •   特色天然产物库 •   天然产物衍生物库 Fragment片段库 •   通用片段库 •   特色片段库 类药性化合物库 •   多样性核心库Part2 •   多样性核心库Part1 化合物库深度定制
技术服务 计算机辅助药物设计 •   虚拟筛选 实体化合物活性筛选 •   分子结合&互作检测 药物设计和结构优化 天然产物 试剂盒 Cell Counting Kit-8 (CCK-8) Inhibitor Cocktails SYBR Green qPCR Master Mix (No ROX) 染料试剂 多肽产品 抗体抑制剂 PROTAC
重组蛋白 细胞因子和生长因子 •   细胞因子 •   生长因子 受体蛋白 •   Fc 受体 •   细胞因子和生长因子受体 •   受体酪氨酸激酶 CD 蛋白 •   T 细胞 CD 蛋白 •   B 细胞 CD 蛋白 免疫检查点蛋白 •   抑制性免疫检查点蛋白 •   刺激性免疫检查点蛋白 CAR-T 细胞治疗靶点蛋白 •   血液恶性肿瘤靶点蛋白 •   实体瘤靶点蛋白
信号通路 血管生成 凋亡 自噬 细胞周期 表观遗传 细胞骨架
DNA损伤和修复 内分泌与激素 G蛋白偶联受体 免疫与炎症 JAK/STAT信号通路 MAPK信号通路 离子通道
代谢 微生物学 神经科学 NF-κB信号通路 氧化还原 PI3K/Akt/mTOR信号通路 蛋白酶体
干细胞 蛋白酪氨酸激酶 泛素化 PROTAC 其他
活性化合物库 上市药物库 临床期小分子药物库 已知活性化合物库 FDA上市及药典收录分子库 抗癌药物库 抗病毒库 铁死亡化合物库
天然产物库 高通量筛选天然产物库 Ro5类药天然产物库 中药单体化合物库 糖类及苷类化合物库 稀有天然产物库 天然产物衍生物库 天然产物单体化合物库
Fragment片段库 高溶解性片段库 精选片段库 高溶解性多官能团片段化合物库 高溶解性卤化片段化合物库 药物片段库 Mini片段亲电杂环化合物库 高溶解性微型片段化合物库
类药性化合物库 多样性核心库Part2 多样性核心库Part1 药物靶点库 多样性核心预制库 Golden骨架库 Mini骨架库 化合物库深度定制
TargetMol Compound Library
天然产物库 高通量筛选天然产物库 特色天然产物库 天然产物衍生物库 虚拟筛选天然产物库
结构类型 萜类 类固醇 类黄酮 醌类 香豆素 木脂素 多糖和糖苷
苯丙烷 生物碱 酚类 其他
植物来源 列当科 水龙骨科 南洋杉科 报春花科 海金沙科 商陆科 买麻藤科
萝藦科 肉豆蔻科 鸭跖草科 交让木科 三白草科 海桐花科 五味子科 红厚壳科
莲叶桐科 胡桃科 石杉科 桔梗科 百合科 忍冬科 漆树科
计算机辅助药物设计 虚拟筛选 分子对接 反向找靶 分子动力学模拟
基于靶点筛选实体化合物活性筛选 分子结合&互作检测 酶学靶点活性检测 核受体靶点活性检测 GPCR靶点活性检测
基于表型筛选实体化合物活性筛选 细胞增殖检测 细胞周期检测 细胞凋亡检测 药代动力学研究
药物设计和结构优化 化合物定制合成 分子砌块 网络药理学平台 软件平台
细胞因子和生长因子 •   细胞因子 •   生长因子 受体蛋白 •   Fc 受体 •   细胞因子和生长因子受体
CD 蛋白 •   T 细胞 CD 蛋白 •   B 细胞 CD 蛋白 免疫检查点蛋白 •   抑制性免疫检查点蛋白 •   刺激性免疫检查点蛋白
CAR-T 细胞治疗靶点蛋白 •   血液恶性肿瘤靶点蛋白 •   实体瘤靶点蛋白 酶 •   氧化还原酶 •   转移酶
病毒蛋白 •   冠状病毒蛋白 •   流感病毒蛋白 荧光蛋白 其他蛋白

搜索结果

Search Results for " d18:1/18:0 "

36

抑制剂 & 化合物

1

天然产物

如果没找到您满意的产品或者您对产品有其他要求，可以联系我们专业顾问为您提供针对性的合理建议。     QQ咨询       网站留言咨询

提交您的定制咨询

点击图片重新获取验证码
Cat. No. Product Name Target Signaling Pathways
T37439 C18 Globotriaosylceramide (d18:1/18:0)

C18 globotriaosylceramide is an endogenous sphingolipid found in mammalian cell membranes that is synthesized from lactosylceramide . It inhibits aggregation of human neutrophils induced by phorbol 12-myristate 13-acetate (PMA; 10008014) when used at a concentration of 1 μM. C18 globotriaosylceramide acts as a receptor for Shiga toxin in B cell-derived Raji cells and THP-1 monocytes. It accumulates in the brain, heart, kidney, liver, lung, and spleen in a mouse model of Fabry disease, a lysosoma...
T37457 C18 L-threo Ceramide (d18:1/18:0)

C18 L-threo Ceramide (d18:1/18:0)
C18 L-threo Ceramide is a synthetic ceramide and stereoisomer of C18 ceramide that has been used for structural characterization of natural sphingolipids. It inhibits rat brain mitochondrial ceramidase (mt-CDase) with an IC50 value of 0.21 mol% (16.8 μM).
T37456 C18 L-erythro Ceramide (d18:1/18:0)

C18 L-erythro Ceramide (d18:1/18:0)
C18 L-erythro Ceramide is a naturally occurring ceramide and stereoisomer of C18 ceramide . It inhibits rat brain mitochondrial ceramidase (mt-CDase) with an IC50 value of 0.11 mol% (8.8 μM).
T38183 C18 3'-sulfo Galactosylceramide (d18:1/18:0)

C18 3'-sulfo Galactosylceramide (d18:1/18:0)
C18 3'-sulfo Galactosylceramide is a member of the sulfatide class of glycolipids. Levels of short-chain sulfatides, including C18 3'-sulfo galactosylceramide, decrease with age in mice and humans. It is increased in brain from mice with an arylsulfatase A deficiency (ASA-KO), particularly in lipid raft fractions. Plasma levels of C18 3'-sulfo galactosylceramide positively correlate with disability progression in patients with relapsing-remitting multiple sclerosis using the Expanded Disability ...
T37455 C18 D-threo Ceramide (d18:1/18:0)

C18 D-threo Ceramide (d18:1/18:0)
C18 D-threoCeramide (d18:1/18:0) is a synthetic ceramide and stereoisomer of C18 ceramide .1It inhibits rat brain mitochondrial ceramidase (mt-CDase) with an IC50value of 16.6 μM.2[Matreya, LLC. Catalog No. 1855] 1.Koolath, S., Murai, Y., Suga, Y., et al.Chiral combinatorial preparation and biological evaluation of unique ceramides for inhibition of sphingomyelin synthaseChirality32(3)308-313(2019) 2.Usta, J., El Bawab, S., Roddy, P., et al.Structural requirements of ceramide and sphingosine bas...
T83880 C18 Ceramide-1-phosphate (d18:1/18:0) ammonium

Ceramide-1-phosphate (d18:1/18:0),N-octadecanoyl-D-erythro-Sphingosine-1-phosphate,C18 Ceramide-1-phosphate,C18 C1P,CerP(d18:1/18:0),N-stearoyl-D-erythro-Sphingosine-1-phosphate
C18 Ceramide-1-phosphate (d18:1/18:0) 是一种在鼠皮肤中发现的长链ceramide-1-phosphate。它能在0.5至5 µM的浓度范围内促进分离的小鼠骨髓来源的多能间充质细胞和人脐静脉内皮细胞（HUVECs）的迁移。与胰腺癌干细胞相比，CFPAC-1胰管腺癌细胞中C18 Ceramide-1-phosphate (d18:1/18:0)的水平有所增加。在Langendorff分离的灌流小鼠心脏的离体缺血模型中，心肌中C18 ceramide-1-phosphate (d18:1/18:0)的水平有所增加。
T37563 C22 Ceramide (d18:1/22:0)

Cer(d18:1/22:0),C22 Ceramide,Ceramide (d18:1/22:0)
C22 Ceramide (d18:1/22:0) (C22 Ceramide) 是一种从海绵Haliclona koremella 中分离出含有山嵛酸的长链神经酰胺，是一种内源性生物活性鞘脂。C22 Ceramide (d18:1/22:0) 可特异性抑制MCSR，降低离体大鼠肝线粒体和脂质体中 C16-神经酰胺通道的形成。
T35806 N-Stearoylsphingosine

C(18:0)/C(18:1),Cer(d18:1/18:0),C18 Ceramide (d18:1/18:0),C18 Ceramide

 Phosphatase Metabolism
N-Stearoylsphingosine (Cer(d18:1/18:0)) 是一种广泛存在真核生物体内的酰胺类化合物，通过干扰PP2A与PP2A抑制剂2的结合来增强蛋白质磷酸酶2A(PP2A)活性，导致Akt去磷酸化。N-Stearoylsphingosine 可用于研究前列腺癌。
T35805 C16 Sphingomyelin (d18:1/16:0)

Sphingomyelin 16:0,N-Palmitoyl-D-sphingomyelin

 Endogenous Metabolite Metabolism
C16 Sphingomyelin (d18:1/16:0) (N-Palmitoyl-D-sphingomyelin) 是磷脂双层膜的磷脂类化合物，可用于研究生物膜的活性。
T36860 C22 Sphingomyelin (d18:1/22:0)

C22 Sphingomyelin (d18:1/22:0)
C22 Sphingomyelin is a naturally occurring form of sphingomyelin . Plasma levels of C22 sphingomyelin positively correlate with hepatic steatosis severity in patients with chronic hepatitis C virus (HCV). C22 Sphingomyelin levels are decreased in T-47D mammary epithelial cells and increased in MDA-MB-231 breast cancer cells relative to C16 sphingomyelin .
T37438 C17 Globotriaosylceramide (d18:1/17:0)

C17 Globotriaosylceramide (d18:1/17:0)
C17 Globotriaosylceramide is a sphingolipid that has been used as an internal standard for the quantification of globotriaosylceramides in plasma and urine from patients with Fabry disease by GC-MS.
T38281 C22 Galactosylceramide (d18:1/22:0)

C22 Galactosylceramide is a sphingolipid that has been found in the central nervous system.1,2C22 Galactosylceramide levels are increased in the spinal cord, but not the brain or liver, of mice fed a methionine-restricted diet.1C22 Galactosylceramide has been found in postmortem hippocampus from patients with Alzheimer's disease.2[Matreya, LLC.]
T37564 C4 Ceramide (d18:1/4:0)

C4 Ceramide (d18:1/4:0),Cer(d18:1/4:0)
C4 Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides. [1] [2] [3] It inhibits IL-4 production by 16% in EL4 T cells stimulated with phorbol 12-myristate 13-acetate when used at a concentration of 10 μM. [1] C4 Ceramide is cytotoxic to SK-BR-3 and MCF-7/Adr breast cancer cells (IC50s = 15.9 and 19.9 μM, respectively). [2] C4 Ceramide also increases maturation and stability of cystic fibrosis transmembrane conductance regulator (CFTR) proteins bearing...
T37872 C16 Galactosylceramide (d18:1/16:0)

C16 Galactosylceramide (d18:1/16:0)
C16 Galactosylceramide is a glycosphingolipid that contains a galactose moiety attached to a ceramide acylated with palmitic acid .
T35809 C20 Sphingomyelin (d18:1/20:0)

C20 Sphingomyelin is a naturally occurring sphingolipid. Levels of C20 sphingomyelin are upregulated in the hippocampus of rats with diabetes induced by streptozotocin and in human plasma where it is positively correlated with insulin resistance in obese humans. C20 sphingomyelin is also upregulated in the liver of a mouse model of Niemann-Pick type C1 disease, a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder. The plasma concentration of C20 sphingomyelin is decreased in m...
T36859 C16 Globotriaosylceramide (d18:1/16:0)

C16 Globotriaosylceramide (d18:1/16:0)
C16 globotriaosylceramide is an endogenous sphingolipid found in mammalian cell membranes that is synthesized from C16 lactosylceramide . C16 globotriaosylceramide acts as a receptor for Shiga toxin in B cell-derived Raji cells and THP-1 monocytes. It accumulates in endothelial cells, pericytes, vascular smooth muscle cells, renal epithelial cells, dorsal ganglia neuronal cells, and myocardial cells in patients with Fabry disease. C16 globotriaosylceramide is also upregulated in plasma of patien...
T35873 C19 Ceramide (d18:1/19:0)

C19 Ceramide (d18:1/19:0)
C19 Ceramide is a naturally occurring ceramide that has been found in J. juncea extracts as well as rat brain and mouse heart.[1],[2],[3] It is elevated in adult and decreased in juvenile whole rat brain extracts by 114 and 37%, respectively, following chronic ethanol exposure.[2] C19 Ceramide is also increased in mouse hearts following administration of angiotensin II.[3]
T36858 C12 Galactosylceramide (d18:1/12:0)

C12 Galactosylceramide is a bioactive sphingolipid. It inhibits IL-4 production by 53.84% in EL4 T cells when used at a concentration of 10 μM. C12 Galactosylceramide reduces the growth of human papillomavirus type 16-associated tumors in mice and reduces tumor recurrence following surgical removal or chemotherapy. It also reduces natural killer T cell activity, delays the onset of proteinuria, and improves survival in a mouse model of systemic lupus.
T38286 C26 Sphingomyelin (d18:1/26:0)

C26 Sphingomyelin (d18:1/26:0)
C26 Sphingomyelin is a sphingolipid that has been found in serum and cell or brain extracts.1,2,3C26 sphingomyelin levels are increased in the serum of patients with hemophagocytic lymphohistiocytosis, an inflammatory condition characterized by excessive immune activation.3C26 sphingomyelin has been used a component of monolayers to study the influence of sphingomyelin acyl chain length on sphingomyelin-sterol interactions.4[Matreya, LLC.] 1.Wang, J.-R., Zhang, H., Yau, L.D., et al.Improved sphi...
T36323 C8 Galactosylceramide (d18:1/8:0)

C8 Galactosylceramide (d18:1/8:0)
C8 Galactosylceramide is a synthetic C8 short-chain derivative of known membrane microdomain-forming sphingolipids. It increases the amount delivered and toxicity of doxorubicin in cancerous but not non-cancerous cells when incorporated into the nanoliposomal membrane of nanoliposomal-doxorubicin. C8 Galactosylceramide induces proliferation and cytokine production by splenocytes in vitro at concentrations ranging from 100-1,000 ng/ml but has no effect on natural killer T cell production in vivo....
T37437 C17 Ceramide (d18:1/17:0)

C17 Ceramide is a synthetic ceramide that contains a non-natural C17:0 fatty acid acylated to sphingosine. It has been used as a marker of arylsulfatase A and sphingolipid activator B activity in patients undergoing enzyme replacement therapy for the genetic disease metachromatic leukodystrophy.
T38282 C22 Glucosylceramide (d18:1/22:0)

C22 Glucosylceramide (d18:1/22:0) is an endogenous glucosylceramide. Glucosylceramides are major constituents of skin lipid membranes where they play a role in maintaining the water permeability barrier. They are precursors in the synthesis of lactosylceramide , as well as oligoglycolipids and gangliosides. Phospholipase A2 (PLA2) type XIIA knockdown increases C22 glucosylceramide (d18:1/22:0) expression in rat brain. It is also increased in the brain, but not the liver or spinal cord, of mice f...
T35804 C16 Lactosylceramide (d18:1/16:0)

C16 Lactosylceramide is an endogenous bioactive sphingolipid. It forms membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs), suggesting a role in cell signaling. Plasma levels of C16 lactosylceramide are elevated in insulin-resistant cattle. C16 Lactosylceramide is also upregulated in a mouse model of Niemann-Pick type C1 disease, a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder.
T38181 C17 Lactosylceramide (d18:1/17:0)

C17 Lactosylceramide is a naturally occurring sphingolipid that has been found in human brain metastases of lung adenocarcinomas but not in healthy brain tissue.
T38182 C17 Sphingomyelin (d18:1/17:0)

C17 Sphingomyelin (d18:1/17:0)
C17 Sphingomyelin is a synthetic derivative of sphingomyelin that has been used as an internal standard for the quantification of sphingomyelin.
T38011 C2 Adamantanyl Globotriaosylceramide (d18:1/2:0)

C2 Adamantanyl globotriaosylceramide (AdaGb3) is a bioactive sphingolipid and water-soluble form of globotriaosylceramide that contains an adamantanyl group in place of the fatty acyl chain. It inhibits Vero toxin binding to globotriaosylceramide in an ELISA assay when used at a concentration of 10 μM. AdaGb3 decreases cell surface expression of P-glycoprotein (P-gp) and reduces efflux of rhodamine 123 in MDCK cells. It also increases apical-to-basal transport of vinblastine in human intestinal ...
T37440 C2 Adamantanyl Galactosylceramide (d18:1/2:0)

C2 Adamantanyl Galactosylceramide (d18:1/2:0) (AdaGalCer) is a bioactive sphingolipid. It reduces globotriaosylceramide 3 synthesis from exogenous lactosylceramide in microsomes. AdaGalCer stimulates recombinant glucocerebrosidase activity in a pH-dependent manner. It activates glucocerebrosidase to decrease glucosylceramide accumulation in fibroblasts and lymphoblasts isolated from patients with Gaucher and Fabry disease, respectively.
T36140 BODIPY-C12 Ceramide (d18:1/12:0)

BODIPY-C12 Ceramide (d18:1/12:0)
BODIPY-C12 Ceramide（B12Cer）是C12鞘氨醇的荧光标记形式，其激发/发射最大值分别为505/540 nm。BODIPY-C12 Ceramide 是一种带有荧光标记的神经酰胺。BODIPY-C12 Ceramide已被用于量化尼曼-匹克病患者血浆中酸性鞘磷脂酶的活性。
T38185 C2 3'-sulfo Galactosylceramide (d18:1/2:0)

C2 3'-sulfo Galactosylceramide (d18:1/2:0)
C2 3'-sulfo Galactosylceramide is a member of the sulfatide class of glycolipids. It has been used as an internal standard in the quantification of lysosulfatides in mouse brain tissue and plasma.
T37565 C6 D-threo Ceramide (d18:1/6:0)

C6 D-threo Ceramide (d18:1/6:0)
C6 D-threo Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides., C6 D-threo Ceramide is cytotoxic to U937 cells in vitro (IC50 = 18 μM). It is metabolically inactive and, unlike C6 L-erythro ceramide , C6 D-threo ceramide cannot be converted to C6 glucosylceramide by ceramide glucosyltransferase. C6 D-threo Ceramide promotes survival of isolated rat spinal neurons when used at concentrations up to 2.5 μM but induces cell death at concentrations greater...
T36320 C6 L-threo Ceramide (d18:1/6:0)

C6 L-threo Ceramide (d18:1/6:0)
C6 L-threo Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides., C6 L-threo Ceramide is cytotoxic to U937 cells in vitro (IC50 = 18 μM). It is metabolically inactive and, unlike C6 L-erythro ceramide , C6 L-threo ceramide cannot be converted to C6 glucosylceramide by ceramide glucosyltransferase. C6 L-threo Ceramide enhances IL-4 production induced by phorbol 12-myristate 13-acetate in EL4 T cells when used at a concentration of 10 μM.
T35927 C2 L-threo Ceramide (d18:1/2:0)

C2 L-threo Ceramide (d18:1/2:0)
C2 L-threo Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides. It stimulates cholesterol efflux in CHO cells expressing the human ABCA1 receptor when used at a concentration of 10 μM, however, this efflux is 50% less than that stimulated by C2 ceramide . C2 L-threo Ceramide inhibits IL-4 production by 17% in EL4 T cells stimulated with phorbol 12-myristate 13-acetate when used at a concentration of 10 μM. It also induces cell cycle arrest in the G0/G1...
T36149 13C C16 Sphingomyelin (d18:1/16:0)

13C C16 Sphingomyelin is an isotopically enriched form of C16 sphingomyelin with carbon-13 occurring on the fatty acid portion. It is intended for use as an internal standard for the quantification of C16 sphingomyelin by GC- or LC-MS. C16 Sphingomyelin is a form of sphingomyelin containing palmitate (16:0) at the variable acylation position. It is the most common form of sphingomyelin found in eggs and is less abundant in the brain and in milk. C16 Sphingomyelin interacts with cholesterol in or...
T36322 C8 D-threo Ceramide (d18:1/8:0)

C8 D-threo Ceramide (d18:1/8:0)
C8 D-threo Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides. It is cytotoxic to U937 cells (IC50 = 17 μM) and induces nuclear DNA fragmentation 5- to 6-fold more potently than C8 ceramide . C8 D-threo Ceramide is a substrate for E. coli diacylglycerol kinase. It activates ceramide-activated protein kinase (CAPK) in U937 cells. C8 D-threo Ceramide also enhances V. cholerae cytolysin pore formation in liposome lipid membranes, as measured by calcein r...
T36319 C6 L-erythro Ceramide (d18:1/6:0)

C6 L-erythro Ceramide (d18:1/6:0)
C6 L-erythro Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides. It is metabolized by ceramide glucosyltransferase to form C6 L-erythro glucosylceramide. C6 L-erythro Ceramide is cytotoxic to U937 cells (IC50 = 18 μM).
T36324 C8 L-threo Ceramide (d18:1/8:0)

C8 L-threo Ceramide (d18:1/8:0)
C8 L-threo Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides. It is cytotoxic to U937 cells (IC50 = 10 μM) and, like C8 D-threo ceramide , induces nuclear DNA fragmentation 5- to 6-fold more potently than C8 L-erythro ceramide . C8 D-threo Ceramide also enhances V. cholerae cytolysin pore formation in liposome lipid membranes, as measured by calcein release, with a 50% release dose (RD50) value of ~30 μg/ml.

化合物

C18 Globotriaosylceramide (d18:1/18:0)
Cat.No: T37439
Synonym:
Target:
C18 L-threo Ceramide (d18:1/18:0)
Cat.No: T37457
Synonym: C18 L-threo Ceramide (d18:1/18:0)
Target:
C18 L-erythro Ceramide (d18:1/18:0)
Cat.No: T37456
Synonym: C18 L-erythro Ceramide (d18:1/18:0)
Target:
C18 3'-sulfo Galactosylceramide (d18:1/18:0)
Cat.No: T38183
Synonym: C18 3'-sulfo Galactosylceramide (d18:1/18:0)
Target:
C18 D-threo Ceramide (d18:1/18:0)
Cat.No: T37455
Synonym: C18 D-threo Ceramide (d18:1/18:0)
Target:
C18 Ceramide-1-phosphate (d18:1/18:0) ammonium
Cat.No: T83880
Synonym: Ceramide-1-phosphate (d18:1/18:0),N-octadecanoyl-D-erythro-Sphingosine-1-phosphate,C18 Ceramide-1-phosphate,C18 C1P,CerP(d18:1/18:0),N-stearoyl-D-erythro-Sphingosine-1-phosphate
Target:
C22 Ceramide (d18:1/22:0)
Cat.No: T37563
Synonym: Cer(d18:1/22:0),C22 Ceramide,Ceramide (d18:1/22:0)
Target:
N-Stearoylsphingosine
Cat.No: T35806
Synonym: C(18:0)/C(18:1),Cer(d18:1/18:0),C18 Ceramide (d18:1/18:0),C18 Ceramide
Target: Phosphatase
C16 Sphingomyelin (d18:1/16:0)
Cat.No: T35805
Synonym: Sphingomyelin 16:0,N-Palmitoyl-D-sphingomyelin
Target: Endogenous Metabolite
C22 Sphingomyelin (d18:1/22:0)
Cat.No: T36860
Synonym: C22 Sphingomyelin (d18:1/22:0)
Target:
C17 Globotriaosylceramide (d18:1/17:0)
Cat.No: T37438
Synonym: C17 Globotriaosylceramide (d18:1/17:0)
Target:
C22 Galactosylceramide (d18:1/22:0)
Cat.No: T38281
Synonym:
Target:
C4 Ceramide (d18:1/4:0)
Cat.No: T37564
Synonym: C4 Ceramide (d18:1/4:0),Cer(d18:1/4:0)
Target:
C16 Galactosylceramide (d18:1/16:0)
Cat.No: T37872
Synonym: C16 Galactosylceramide (d18:1/16:0)
Target:
C20 Sphingomyelin (d18:1/20:0)
Cat.No: T35809
Synonym:
Target:
C16 Globotriaosylceramide (d18:1/16:0)
Cat.No: T36859
Synonym: C16 Globotriaosylceramide (d18:1/16:0)
Target:
C19 Ceramide (d18:1/19:0)
Cat.No: T35873
Synonym: C19 Ceramide (d18:1/19:0)
Target:
C12 Galactosylceramide (d18:1/12:0)
Cat.No: T36858
Synonym:
Target:
C26 Sphingomyelin (d18:1/26:0)
Cat.No: T38286
Synonym: C26 Sphingomyelin (d18:1/26:0)
Target:
C8 Galactosylceramide (d18:1/8:0)
Cat.No: T36323
Synonym: C8 Galactosylceramide (d18:1/8:0)
Target:
C17 Ceramide (d18:1/17:0)
Cat.No: T37437
Synonym:
Target:
C22 Glucosylceramide (d18:1/22:0)
Cat.No: T38282
Synonym:
Target:
C16 Lactosylceramide (d18:1/16:0)
Cat.No: T35804
Synonym:
Target:
C17 Lactosylceramide (d18:1/17:0)
Cat.No: T38181
Synonym:
Target:
C17 Sphingomyelin (d18:1/17:0)
Cat.No: T38182
Synonym: C17 Sphingomyelin (d18:1/17:0)
Target:
C2 Adamantanyl Globotriaosylceramide (d18:1/2:0)
Cat.No: T38011
Synonym:
Target:
C2 Adamantanyl Galactosylceramide (d18:1/2:0)
Cat.No: T37440
Synonym:
Target:
BODIPY-C12 Ceramide (d18:1/12:0)
Cat.No: T36140
Synonym: BODIPY-C12 Ceramide (d18:1/12:0)
Target:
C2 3'-sulfo Galactosylceramide (d18:1/2:0)
Cat.No: T38185
Synonym: C2 3'-sulfo Galactosylceramide (d18:1/2:0)
Target:
C6 D-threo Ceramide (d18:1/6:0)
Cat.No: T37565
Synonym: C6 D-threo Ceramide (d18:1/6:0)
Target:
C6 L-threo Ceramide (d18:1/6:0)
Cat.No: T36320
Synonym: C6 L-threo Ceramide (d18:1/6:0)
Target:
C2 L-threo Ceramide (d18:1/2:0)
Cat.No: T35927
Synonym: C2 L-threo Ceramide (d18:1/2:0)
Target:
13C C16 Sphingomyelin (d18:1/16:0)
Cat.No: T36149
Synonym:
Target:
C8 D-threo Ceramide (d18:1/8:0)
Cat.No: T36322
Synonym: C8 D-threo Ceramide (d18:1/8:0)
Target:
C6 L-erythro Ceramide (d18:1/6:0)
Cat.No: T36319
Synonym: C6 L-erythro Ceramide (d18:1/6:0)
Target:
C8 L-threo Ceramide (d18:1/8:0)
Cat.No: T36324
Synonym: C8 L-threo Ceramide (d18:1/8:0)
Target:
Cat. No. Product Name Target Signaling Pathways
T41338 C30(ω-hydroxy) Ceramide (d18:1/30:0)

C30(ω-hydroxy) Ceramide (d18:1/30:0) 在生命科学相关研究中具有广泛的应用。

天然产物

C30(ω-hydroxy) Ceramide (d18:1/30:0)
Cat.No: T41338
Synonym:
Target:
TargetMol®
关于我们 隐私声明 前沿资讯 相关条款
相关支持
联系我们 全球经销商 订购指南 技术支持
技术资源
产品目录 产品引用文献 信号通路 溶液计算器
订阅 TargetMol®
订阅以获得我们的产品更新和特惠活动!
获取我们的最新产品和特惠活动!
TargetMol®
相关支持
技术资源
我们的所有产品和服务仅用于科学研究，不能被用于人体，我们也不向个人提供产品和服务。
Copyright © 2015-2024 TargetMol Chemicals Inc. All rights reserved. 沪ICP备20019793号-4 沪公网安备 31010602006700号 沪公网安备 31010602006700号
联系我们
400-820-0310
service@tsbiochem.com
2881945090（终端用户）
2885109491（经销商） 

上海市静安区江场三路238号8楼